Differential diagnosis of fever and rash cases negative for measles and rubella to complement surveillance activities
Journal of Medical Virology · 2023
DOI: 10.1002/jmv.29141 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Virology, 2023. Verfasst von Clara Fappani und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Sciences, Università degli Studi di Milano, Milan, Italy. Hauptthemen laut MEDLINE: Epstein-Barr Virus Infections, Measles, Rubella, Enterovirus. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
In the quest to eliminate measles virus (MV) and rubella virus (Ruv), every suspected case must be properly identified and diagnosed. Since 2017, in Milan (Italy), a total of 978 measles and rubella suspected cases (fever and rash) were investigated and 310 were not laboratory confirmed (discarded cases). To improve surveillance activities, we investigated the presence in discarded cases of 8 other viral pathogens commonly associated with rash: human herpesvirus 6 (HHV‐6) and 7 (HHV‐7), parvovirus B19 (B19V), enterovirus (EV), Epstein−Barr virus (EBV), human adenovirus (HAdV), cytomegalovirus (HCMV), and SARS‐CoV‐2. Differential diagnosis was carried out on 289 discarded cases by multiplex real‐time PCR assays. At least one pathogen was detected in 188 cases (65.1%) with HHV‐7 being the most frequently detected virus. No difference in the number of detected infections overtime was observed and infections were identified in all age groups. As expected, most HHV‐6, EV, HAdV, and HCMV‐positive cases were found in children aged 0−4 years and HHV‐7 was most frequent in the 15−39 age group. In light of the World Health Organization measles elimination goal, the introduction of laboratory methods for differential diagnosis is required for the final classification of clinically compatible cases. The used screening panel allowed us to increase the percentage of virus‐positive cases to 87.5%, allowing us to clarify viral involvement and epidemiology, improve diagnosis, and strengthen surveillance activities. As all investigated pathogens were detected, this diagnostic panel was a suitable tool to complement MV and RuV surveillance activities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Health Sciences, Università degli Studi di Milano, Milan, Italy.
- Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milan, Italy.
- Coordinate Research Centre EpiSoMI (Epidemiology and Molecular Surveillance of Infections), Università degli Studi di Milano, Milan, Italy.
- Centre for Multidisciplinary Research in Health Science (MACH), Università degli Studi di Milano, Milan, Italy.
- Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.
ORCID-Profile: Clara Fappani, Maria Gori, Silvia Bianchi, Daniela Colzani, Elisabetta Tanzi, Marta Canuti, Antonella Amendola
Zitieren
APA
Fappani, C., Gori, M., Bianchi, S., Terraneo, M., Bilardi, E., Colzani, D., Tanzi, E., Canuti, M., & Amendola, A. (2023). Differential diagnosis of fever and rash cases negative for measles and rubella to complement surveillance activities. Journal of Medical Virology. https://doi.org/10.1002/jmv.29141
Vancouver
Fappani C, Gori M, Bianchi S, Terraneo M, Bilardi E, Colzani D, et al. Differential diagnosis of fever and rash cases negative for measles and rubella to complement surveillance activities. Journal of Medical Virology. 2023. doi:10.1002/jmv.29141
BibTeX
@article{Fappani2023,
author = {Fappani, Clara and Gori, Maria and Bianchi, Silvia and Terraneo, Mara and Bilardi, Erica and Colzani, Daniela and Tanzi, Elisabetta and Canuti, Marta and Amendola, Antonella},
title = {Differential diagnosis of fever and rash cases negative for measles and rubella to complement surveillance activities},
journal = {Journal of Medical Virology},
year = {2023},
doi = {10.1002/jmv.29141}
}
EUVIMED